A consensus has been growing about the inequitable readings of pulse oximeters, which measure blood oxygen levels, and the FDA discussed the matter in November 2022. The agency has been working to test the accuracy of pulse oximeters in diverse populations, but the attorneys general letter said pulse oximeters still lack clear warning labels.
The second meeting, marked for Feb. 2, will center on improving study methods that account for patients’ skin pigmentation, race and ethnicity.
